PIM
GPCR icon

Platinum Investment Management’s Structure Therapeutics GPCR Stock Holding History

Platinum Investment Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.85M Buy
90,363
+23,499
+35% +$1.04M 1.19% 26
2026
Q1 		$3.22M Sell
66,864
-21,010
-24% -$1.44M 0.81% 46
2025
Q4 		$6.11M Sell
87,874
-34,884
-28% -$1.42M 1.41% 15
2025
Q3 		$3.44M Buy
122,758
+47,858
+64% +$953K 0.22% 48
2025
Q2 		$1.55M Hold
74,900
– – 0.1% 64
2025
Q1 		$1.3M Hold
74,900
– – 0.08% 65
2024
Q4 		$2.03M Buy
74,900
+17,670
+31% +$627K 0.12% 61
2024
Q3 		$2.51M Hold
57,230
– – 0.11% 62
2024
Q2 		$2.25M Sell
57,230
-19,863
-26% -$816K 0.09% 63
2024
Q1 		$3.3M Hold
77,093
– – 0.13% 54
2023
Q4 		$3.14M Buy
77,093
+24,632
+47% +$1.41M 0.13% 66
2023
Q3 		$2.65M Buy
52,461
+37,461
+250% +$1.21M 0.1% 69
2023
Q2 		$624K Hold
15,000
– – 0.02% 102
2023
Q1 		$357K Buy
+15,000
New +$352K 0.01% 111

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Platinum Investment Management's GPCR Position: Q2 2026 in Review

Platinum Investment Management increased its Structure Therapeutics (GPCR) stake by 35% in Q2 2026, buying an estimated $1.04M and bringing the position to 90,363 shares worth $4.85M. The position accounts for 1.19% of the portfolio, ranked #26.

Platinum Investment Management first reported a position in GPCR in Q1 2023 and has held it in 14 quarters since. The position peaked at $6.11M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Platinum Investment Management held 90,363 shares of Structure Therapeutics worth $4.85M as of Q2 2026.
  • Platinum Investment Management bought 23,499 Structure Therapeutics shares in Q2 2026, an estimated $1.04M.
  • Structure Therapeutics made up 1.19% of Platinum Investment Management's portfolio in Q2 2026, its #26 holding.
  • Platinum Investment Management first reported a position in Structure Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Platinum Investment Management's Structure Therapeutics position peaked at $6.11M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Platinum Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.